Table 1_Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database.docx

Table 1_Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database.docx

Introduction<p>Eculizumab is a C5 complement inhibitor approved by the FDA for the targeted treatment of four rare diseases, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and aquaporin-4 immunoglobulin G-positive opti...

Full description

Saved in:
Bibliographic Details
Main Author: Xi-Feng Wang (6443420) (author)
Other Authors: Lu-Ri Bao (20532359) (author), Ta-La Hu (20532362) (author), Rui-Feng Xu (20532365) (author), Wu-Niri Gao (20532368) (author), Jing-Yuan Wang (1592689) (author), Jian-Rong Zhao (20532371) (author), Zhen-Li Fu (20532374) (author), Yan Meng (28903) (author), Shu-Fang Wang (228296) (author)
Published: 2025
Subjects:
Pharmacology
eculizumab
FAERS
adverse drug events
adverse drug reaction monitoring
ADRM
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items